Long-term outcomes of diabetes after laparoscopic Roux-en-Y gastric bypass in a Lebanese bariatric practice
- 2 Downloads
Roux-Y-gastric bypass (RYGB) is highly effective in treating obesity related type II diabetes mellitus (DM). There are a few studies from the Middle East and North Africa (MENA) on the impact of RYGB on DM.
The aim of our study was to evaluate the impact of RYGB on DM in our patient population.
We retrospectively reviewed our database and selected obese patients with type II DM who underwent primary laparoscopic RYGB from 2005 to 2015. Complete remission (CR) of DM was defined as HbA1c < 5.7%, FBG < 100 mg/dL without medications. Partial remission (PR) was defined as HbA1c 5.7–6.4%, FBG 100–125 mg/dL without medications. Improvement was defined by a significant reduction in HbA1c (> 1%) or FBG (> 25 mg/dL) or reduction in HbA1c and FBG accompanied by discontinuing insulin.
Out of 245 RYGB patients, 107 had DM. In comparison, diabetic patients were older and had more hypertension and dyslipidemia. At 5 years with a follow-up (F/U) of 56%, total weight loss in diabetics (24.7%) was lower than non-diabetics (27.7%). At a mean F/U of 5.6 ± 2.7 years, range (1.4 to 10.7), there was a significant reduction in HbA1C (7.9 to 6.1%), FBG (158 to 111 mg/dL), intake of oral hypoglycemic (73.6 to 29.7%), as well as insulin therapy (15.4 to 2.2%). The rate of DM CR was 42.3%, PR 20.5%, improvement 23.1%, and no change 14.1%.
This is the first report from the MENA region on the long-term outcomes of RYGB in the treatment of type II DM. The results are similar to those in the international literature.
KeywordsGastric bypass Diabetes Remission Long-term Lebanon
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
For this type of study, formal consent is not required.
- 3.Ikramuddin S, Korner J, Lee W, et al. Roux-en-y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial. JAMA. 2013;309(21):2240–9. https://doi.org/10.1001/jama.2013.5835.CrossRefGoogle Scholar
- 4.Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. https://doi.org/10.1001/jama.2014.5988.CrossRefGoogle Scholar
- 5.Espinosa O, Pineda O, Maydon HG, Sepulveda EM, Guilbert L, Amado M, et al. Type 2 diabetes mellitus outcomes after laparoscopic gastric bypass in patients with BMI <35 kg/m(2) using strict remission criteria: early outcomes of a prospective study among Mexicans. Surg Endosc. 2018;32(3):1353–9. https://doi.org/10.1007/s00464-017-5815-3.CrossRefGoogle Scholar
- 9.Jimenez A, Casamitjana R, Flores L, Viaplana J, Corcelles R, Lacy A, et al. Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg. 2012;256(6):1023–9. https://doi.org/10.1097/SLA.0b013e318262ee6b.CrossRefGoogle Scholar
- 13.Abusnana S, Abdi S, Tagure B, Elbagir M, Maleckas A. Bariatric surgery outcomes: a single-center study in the United Arab Emirates. Diabetes Metab Syndr Obes. 2015;8:461–71.Google Scholar
- 24.Chen J-C, Hsu N-Y, Lee W-J, Chen S-C, Ser K-H, Lee Y-C. Prediction of type 2 diabetes remission after metabolic surgery: a comparison of the individualized metabolic surgery score and the ABCD score. Surg Obes Relat Dis. 2018;14:640–5. https://doi.org/10.1016/j.soard.2018.01.027.CrossRefGoogle Scholar